


# Natraj Proteins Limited

SOLVENT EXTRACTION PLANT & REFINERY  
Nagpur Kalan, Ordinance Factory Road, ITARSI

Ph.No. 07572- 262637, 262640, Fax No. 07572-262639

Email : natrajproteinltd@rediffmail.com

CIN : L00153 MP 1990 PLC 006090



Ref. :

NPL/SE/2020

Online filing at [www.listing.bseindia.com](http://www.listing.bseindia.com)

Date :

14<sup>th</sup> July, 2020

To,  
The General Manager  
DCS-CRD  
BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort  
MUMBAI - 400001

BSE CODE: 530119

Subject: Submission of the Standalone Audited Financial Results along with Auditors' Report thereon for the Quarter/Year ended 31<sup>st</sup> March, 2020 as per Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015.

Dear Sir/Madam,

This is in continuation of our letter no. NPL/SE/2020 dated 18<sup>th</sup> June, 2020 and NPL/SE/2020 dated 27<sup>th</sup> June, 2020 regarding intimation for Board meeting for consideration and approval of the Standalone Audited Financial Results alongwith Statement of Assets and Liabilities and Cash flow Statement for the quarter/year ended 31<sup>st</sup> March, 2020.

Pursuant to Regulation 33(3)(d) of SEBI (LODR) Regulations, 2015, we are pleased to submit the Standalone Audited Financial Results along with Auditors' Report thereon by Statutory Auditors for the quarter/year ended on 31<sup>st</sup> March, 2020, in PDF Format, which were also approved by the Audit Committee and Board of Directors at their meeting held on Tuesday, 14<sup>th</sup> July, 2020.

Since, the Auditor's Report is self-explanatory and has no modification/qualification, it needs no further comments by the Company.

We are also in process to file the aforesaid financial results in XBRL format within the stipulated time and same shall also be hosted at the website of the company [www.natrajproteins.com](http://www.natrajproteins.com).

The Financial Results will also be published in widely circulated English and Hindi (Vernacular) newspaper in the prescribed format for that purpose.

You are requested to take on record the Standalone Audited Financial Results, Statement of Assets and Liabilities and Cash flow Statement along with Auditor's Report for your reference and record.

Thanking You,  
Yours Faithfully,

For, NATRAJ PROTEINS LIMITED



KAILASH CHAND SHARMA  
CHAIRMAN & MANAGING DIRECTOR  
DIN: 00012900

Encl.: Auditor's Report along with Standalone & Consolidated Audited Financial Results.



## ANUP SHRIVASTAVA & ASSOCIATES CHARTERED ACCOUNTANTS

When an Unmodified Opinion is expressed on the Quarterly financial results for companies (other than banks and insurance companies) - Audited standalone quarterly and year to date

**Auditor's Report On Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

TO, THE BOARD OF DIRECTORS OF  
NATRAJ PROTEINS LTD, ITARSI

We have audited the quarterly financial results of NATRAJ PROTEINS LIMITED, ITARSI for the quarter ended 31st March 2020 and the year to date results for the period 01 April 2019 to 31st March 2020, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- ii. give a true and fair view of the net profit and other financial information for the quarter ended 31st March 2020 as well as the year to date results for the period from 01 April 2019 to 31st March 2020.

For M/s Anup Shrivastava & Associates  
Chartered Accountants

  
CA. Sudeep Moitra  
(Partner)

M.No.: 400340  
FRN: 006455C

Place: BHOPAL

Date: 14-07-2020

UDIN: 20400340AAAABT5926

# NATRAJ PROTEINS LIMITED

CIN: L00153MP1990PLC006090

Regd. Off. - Nagpur Kalan, Ordinance Factory Road, Itarsi, (M.P.)-461111

Email: natrajproteinltd@rediffmail.com

## Statement of Standalone Audited Financial Results for the quarter and Year ended on 31<sup>st</sup> March, 2020

S. No.	Particulars	(Rs. in Lakhs except EPS)				
		3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Previous year ended
	(Refer Notes Below)	31/03/2020	31/12/2019	31/03/2019	31/03/2020	31/03/2019
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I	Revenue from Operations	3707.94	6923.93	3873.47	15412.86	19072.32
II	Other Income	1.17	0.18	16.15	4.60	21.28
III	<b>Total Income (I+II)</b>	<b>3709.11</b>	<b>6924.11</b>	<b>3889.62</b>	<b>15417.46</b>	<b>19093.60</b>
IV	<b>Expenses</b>					
a	Cost of Materials consumed	2805.97	5550.81	3509.60	12150.19	16692.35
b	Purchase of stock-in-trade	205.28	260.59	257.59	1734.22	824.48
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	472.15	747.60	(296.70)	480.87	(210.66)
d	Employee benefits expense	35.34	33.68	26.42	132.23	124.60
e	Finance Costs	86.72	72.68	66.69	361.09	420.81
f	Depreciation and amortization expense	16.00	14.83	16.89	63.17	65.03
g	Other expenses	121.87	184.74	223.72	463.28	1041.66
	<b>Total Expenses (IV)</b>	<b>3743.33</b>	<b>6864.93</b>	<b>3804.21</b>	<b>15385.05</b>	<b>18958.27</b>
V	<b>Profit / (Loss) before extraordinary items, exceptional items and Tax (I-IV)</b>	<b>(34.22)</b>	<b>59.18</b>	<b>85.41</b>	<b>32.41</b>	<b>135.33</b>
VI	Exceptional Items	-	-	-	-	-
VII	<b>Profit / (Loss) before extraordinary items and tax (V-VI)</b>	<b>(34.22)</b>	<b>59.18</b>	<b>84.41</b>	<b>32.41</b>	<b>135.33</b>
VIII	Extra-Ordinary items	-	-	-	-	-
IX	<b>Profit / (Loss) before tax (VII-VIII)</b>	<b>(34.22)</b>	<b>59.18</b>	<b>84.41</b>	<b>32.41</b>	<b>135.33</b>
X	Tax expense					
(1)	Current Tax	(9.10)	12.19	12.28	4.62	27.86
(2)	Deferred Tax	-	-	(7.19)	(6.10)	(7.19)
XI	<b>Profit / (Loss) for the period from continuing operations (IX-X)</b>	<b>(25.12)</b>	<b>46.99</b>	<b>80.32</b>	<b>33.89</b>	<b>114.66</b>
XII	Profit / (Loss) from Discontinuing operations (Before tax)	-	-	-	-	-
XIII	Tax expenses from Discontinuing operations	-	-	-	-	-
XIV	Profit / (Loss) from Discontinuing operations (after Tax) (XII-XIII)	-	-	-	-	-
XV	<b>Net Profit / (Loss) for the period (XI+XIV)</b>	<b>(25.12)</b>	<b>46.99</b>	<b>80.32</b>	<b>33.89</b>	<b>114.66</b>
XVI	Share of Profit/(Loss) of Associates	-	-	-	-	-
XVII	Share of Profit/(Loss) of Minority	-	-	-	-	-
XVIII	Net Profit/ (Loss) after taxes, minority interest and share of profit/(loss) of associates	-	-	-	-	-
XIX	Other Comprehensive Income:					
	A (i) Items that will not be reclassified to Profit or loss	(3.76)	0.83	(2.64)	(2.77)	1.78
	(ii) Income Tax relating to items that will not be reclassified to Profit or loss	-	(0.17)	-	0.43	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or loss	-	-	-	-	-



XX	Total Comprehensive Income for the period (XVIII +XIX) (Comprising profit/(Loss) and other comprehensive income for the period)	(28.88)	47.65	77.68	31.55	116.44
XXI	Paid-up Share Capital of the Company (Face Value Rs. 10/-)	374.70	374.70	374.70	374.70	374.70
XXII	Reserves Excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	-	-	-	3188.97	3163.54
XXIII	Earnings Per Share (for continuing operations)					
	(a) Basic	(0.77)	1.25	2.14	0.90	3.06
	(b) Diluted	(0.77)	1.25	2.14	0.90	3.06
XXIV	Earnings Per Share (for Discontinued operations)					
	(a) Basic	-	-	-	-	-
	(b) Diluted	-	-	-	-	-
XXV	Earnings Per Share (for Discontinued and continuing operations)					
	(a) Basic	(0.77)	1.25	2.14	0.90	3.06
	(b) Diluted	(0.77)	1.25	2.14	0.90	3.06

**Note :-**

- The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 14<sup>th</sup> July, 2020.
- The above financial results are prepared in compliance with Indian Accounting Standards ("IND-AS") as notified under Section 133 of the Companies Act, 2013 ("the Act") [Companies (Indian Accounting Standards) Rules, 2015] as amended.
- The company operates in two segments i.e. solvent extraction and commodities derivative trading. However, for the current quarter as well as corresponding quarter in previous year there is no requirement of segmental reporting as the sales of commodities/derivatives are less than the threshold limits.
- The Statutory Auditors of the company have carried out Audit of the Books of Account for the Financial Year 2019-20 and issued us an Audit Report with Unmodified Opinion on Audited Financial Results for the Quarter/Year ended 31.03.2020, therefore the company is not required to give Statement of Impact of Audit Qualification for Audit Report with Modified Opinion.
- Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
- Effective from 1<sup>st</sup> April, 2019, the company has adopted Indian Accounting Standard (IND-AS 116) "Leases" using the "Modified Prospective Approach". The adoption of the said IND AS did not have any impact on the retained earnings as at 1<sup>st</sup> April, 2019 and there was no material impact on financial results for the quarter/Year ended on 31<sup>st</sup> March, 2020.
- Covid-19 Impact on Financial Results:-**  
The operations of the Company were completely suspended w.e.f. 25<sup>th</sup> March, 2020 as per the directives of Government due to Covid-19 pandemic and now resumed in a phased manner taking into account directives from the Government. As a result of lockdown the volume for the month of March, 2020 have been affected and consequently, the performance for the Month of March, 2020 and the current quarter has also been affected. The Company has evaluated the impact of this pandemic on its business operations, liquidity and financial position and based on management review of current indicators and economic conditions, there is some impact on its financial results as at 31<sup>st</sup> March, 2020. The impact assessment of Covid-19 is a continuing process given the uncertainties associated with its nature and duration. Accordingly the impact may be different from that estimated as at the date of approval of these financial results. The company will continue to monitor any martial changes to future economic conditions.

**For, NATRAJ PROTEINS LIMITED**


Date: 14.07.2020  
Place: Itarsi

**KAILASH CHAND SHARMA**  
Chairman & Managing Director  
DIN: 00012900



## Statement of Audited Standalone Assets and Liabilities as on 31.03.2020

Statement of Assets and Liabilities		(Rupees in Lakhs)	
Particulars	Note No.	Figures as at the end of current reporting period 31/03/2020	Figures as at the end of previous reporting period 31/03/2019
1	2	3	4
		Audited	Audited
<b>ASSETS</b>			
<b>(1) Non-Current Assets</b>			
(a) Property, Plant and Equipment		305.97	353.59
(b) Capital Work-in-Progress		-	-
(c) Investment Property		-	-
(d) Goodwill		-	-
(e) Other Intangible assets		-	-
(f) Intangible assets under development		-	-
(g) Biological Assets other than bearer plants		-	-
(h) Financial Assets			
i. Investments		-	-
ii. Trade receivables		-	-
iii. Loans		77.13	91.70
iv. Others (to be specified)		-	-
(i) Deferred tax assets(net)		-	-
(j) Other non-current assets		155.23	162.94
<b>Total Non-Current Assets</b>		<b>538.33</b>	<b>608.23</b>
<b>(2) Current Assets</b>			
(a) Inventories		4218.25	4113.99
(b) Financial Assets			
i. Investments		-	-
ii. Trade receivables		1784.66	1984.51
iii. Cash and cash equivalents		44.57	6.37
iv. Bank balances other than (iii) above		189.62	405.49
v. Loans		293.69	105.00
vi. Other (to be specified)		-	-
(c) Current Tax Assets (Net)		10.30	0.67
(d) Other current assets		-	-
<b>Total Current Assets</b>		<b>6541.09</b>	<b>6616.03</b>
<b>Total Assets</b>		<b>7079.42</b>	<b>7224.26</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Equity</b>			
(a) Equity Share Capital		374.70	374.70
(b) Other Equity		3188.97	3163.54
<b>Liabilities</b>			
<b>(1) Non-current liabilities</b>			
(a) Financial Liabilities			
(i) Borrowings		-	-
(ii) Trade payables			
- Total outstanding dues of Micro and small enterprises;		-	-
- Total outstanding dues of creditors other than Micro and small enterprises;		-	-
(iii) Other Financial liabilities (other than those specified in item (b), to be specified)		0.00	5.00
(b) Provisions		-	-
(c) Deferred tax liabilities (Net)		86.80	92.90
(d) Other non-current liabilities		-	-
<b>Total Non-Current Liabilities</b>		<b>86.80</b>	<b>97.90</b>
<b>(2) Current liabilities</b>			
(a) Financial Liabilities			
(i) Borrowings		3085.72	3082.22
(ii) Trade payables		-	-



- Total outstanding dues of Micro and small enterprises;		210.40	392.91
- Total outstanding dues of creditors other than Micro and small enterprises;			
(iii) Other Financial liabilities (other than those specified in item (c))		-	-
(b) Other current liabilities		127.18	112.59
(c) Provisions		5.65	0.40
(d) Current Tax Liabilities (Net)		-	-
<b>Total Current Liabilities</b>		<b>3428.95</b>	<b>3588.12</b>
<b>Total Equity and Liabilities</b>		<b>7079.42</b>	<b>7224.26</b>

For, NATRAJ PROTEINS LIMITED

Date: 14.07.2020  
Place: Itarsi

KAILASH CHAND SHARMA  
Chairman & Managing Director  
DIN: 00012900



# CASH FLOW STATEMENT

## FOR THE YEAR ENDED 31<sup>ST</sup> MARCH, 2020

PARTICULARS	YEAR ENDED 31.03.2020	YEAR ENDED 31.03.2019
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net Profit Before Tax	3,155,354	13,757,510
<b>Adjustments for:</b>		
<b>ADD</b>		
Depreciation & Amortization	6,317,370	6,502,619
Interest Charges	36,109,210	42,080,758
<b>LESS</b>		
Interest Income	460,849	641,238
CSR Expenses	612,158	707,975
Deferred Tax Asset	610,155	-
<b>Operating Profit Before Working Capital Changes</b>	<b>43,898,772</b>	<b>60,991,674</b>
<b>Adjustments for :</b>		
Trade Receivables	19,985,023	-55,187,797
Inventories	(10,425,519)	402,452,651
Loans, Advances and other current assets	(18,332,158)	6,182,863
Current Liabilities	(16,267,377)	-114,700,406
Income Tax Paid during the year	(1,500,000)	-2,900,000
Total Adjustments	(26,540,031)	235,847,313
<b>CASH GENERATED FROM OPERATING ACTIVITIES (A)</b>	<b>17,358,741</b>	<b>296,838,987</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of Fixed asset Asset/ Capital WIP	(1,555,370)	(4,773,456)
Interest Received	460,849	641,238
Non Current Assets, Long term loans and advances	2,227,739	19,760,484
<b>NET CASH USED IN INVESTING ACTIVITIES (B)</b>	<b>1,133,218</b>	<b>15,628,266</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from Long Term Borrowings	(500,000)	250,000
Proceeds of Short Term Borrowings Banks	350,234	-232,816,972
Interest Paid	(36,109,210)	(42,080,758)
<b>NET CASH (USED)/FROM FINANCING ACTIVITIES (C)</b>	<b>(36,258,976)</b>	<b>(275,147,730)</b>
<b>NET INCREASE/(DECREASE) IN CASH &amp; CASH EQUIVALENTS (A+B+C)</b>	<b>(17,767,018)</b>	<b>37,319,523</b>
Cash and Cash Equivalents - Opening Balance	41,185,849	3,866,327
Cash and Cash Equivalents - Closing Balance	23,418,831	41,185,849
Increase/Decrease in Closing Cash Balance	(17,767,018)	37,319,522
<b>Cash and Cash Equivalents include:</b>		
(a) Cash on Hand	4,457,053	637,433



(b) Balances with Banks in Current Accounts

18,961,778

40,548,416

(c) Balances in FDR with Bank - No lien deposits

-

-

23,418,831

41,185,849

For, NATRAJ PROTEINS LIMITED

Date: 14.07.2020

Place: Itarsi

**KAILASH CHAND SHARMA**  
Chairman & Managing Director  
DIN: 00012900



# Natraj Proteins Limited

SOLVENT EXTRACTION PLANT & REFINERY  
Nagpur Kalan, Ordinance Factory Road, ITARSI

Ph.No. 07572- 262637, 262640, Fax No. 07572-262639

Email : natrajproteinltd@rediffmail.com

CIN : L00153 MP 1990 PLC 006090



Ref. :

Date :

NPL/SE/2020

Online filing at [www.listing.bseindia.com](http://www.listing.bseindia.com)

14<sup>th</sup> July, 2020

To,  
The General Manager  
DCS-CRD  
BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort  
MUMBAI - 400001

BSE CODE: 530119

Sub.; Submission of declaration as per Second proviso to the Regulation 33(3) of the SEBI (LODR) Regulation, 2015 for the Annual Audited Standalone Financial Results for the year ended 31<sup>st</sup> March, 2020.

Dear Sir,

We hereby submit the following declaration regarding unmodified Auditors Report on the Audited Standalone Financial Results/Statements for the year 31<sup>st</sup> March, 2020 as audited by the Auditors of the Company.

## DECLARATION

Pursuant to SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015, and Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated 25<sup>th</sup> May, 2016 and further amendment vide Circular No. CIR/CFD/CMD/56/2016 dated 27<sup>th</sup> May, 2016 and Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016 issued by the SEBI. We, the undersigned do hereby declare that in the Audit Report, accompanying the Annual Audited Standalone Financial Statements of the Company for the financial year ended on 31<sup>st</sup> March 2020, the Auditor has not expressed any Modified Opinion(s)/ Audit Qualification(s)/ or other Reservation(s) and accordingly the statement on impact of audit qualifications is not required to be given.

You are requested to please consider and take on record the same.

Thanking you  
Yours faithfully

For, Natraj Proteins Limited

For, Natraj Proteins Limited

  
Kailash Chand Sharma  
Chairman & Managing Director  
DIN: 00012900



  
Ritesh Sharma  
Chief Financial Officer

Date: 14.07.2020

Place: Itarsi